Connection

DAVID NELSON to Male

This is a "connection" page, showing publications DAVID NELSON has written about Male.
Connection Strength

0.442
  1. A near telomere-to-telomere phased reference assembly for the male mountain gorilla. Sci Data. 2025 May 22; 12(1):842.
    View in: PubMed
    Score: 0.038
  2. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Netw Open. 2019 06 05; 2(6):e194765.
    View in: PubMed
    Score: 0.025
  3. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-35.
    View in: PubMed
    Score: 0.019
  4. The Fragile X proteins Fmrp and Fxr2p cooperate to regulate glucose metabolism in mice. Hum Mol Genet. 2015 Apr 15; 24(8):2175-84.
    View in: PubMed
    Score: 0.018
  5. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J Neurophysiol. 2009 May; 101(5):2572-80.
    View in: PubMed
    Score: 0.012
  6. Fragile X-related proteins regulate mammalian circadian behavioral rhythms. Am J Hum Genet. 2008 Jul; 83(1):43-52.
    View in: PubMed
    Score: 0.012
  7. Argonaute-2-dependent rescue of a Drosophila model of FXTAS by FRAXE premutation repeat. Hum Mol Genet. 2007 Oct 01; 16(19):2326-32.
    View in: PubMed
    Score: 0.011
  8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. J Crit Care. 2007 Jun; 22(2):142-52.
    View in: PubMed
    Score: 0.011
  9. Care Models to Improve Pain and Reduce Opioids Among Patients Prescribed Long-Term Opioid Therapy: The VOICE Randomized Clinical Trial. JAMA Intern Med. 2025 Feb 01; 185(2):208-220.
    View in: PubMed
    Score: 0.009
  10. Genetics. The critical region in trisomy 21. Science. 2004 Oct 22; 306(5696):619-21.
    View in: PubMed
    Score: 0.009
  11. Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice. Genomics. 2002 Oct; 80(4):423-32.
    View in: PubMed
    Score: 0.008
  12. LLPS of FXR1 drives spermiogenesis by activating translation of stored mRNAs. Science. 2022 08 12; 377(6607):eabj6647.
    View in: PubMed
    Score: 0.008
  13. Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndrome. Proc Natl Acad Sci U S A. 2022 05 31; 119(22):e2118124119.
    View in: PubMed
    Score: 0.008
  14. Impaired conditioned fear and enhanced long-term potentiation in Fmr2 knock-out mice. J Neurosci. 2002 Apr 01; 22(7):2753-63.
    View in: PubMed
    Score: 0.008
  15. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet. 2001 Sep 15; 10(19):2171-9.
    View in: PubMed
    Score: 0.007
  16. Prevalence and cardiometabolic correlates of ketohexokinase gene variants among UK Biobank participants. PLoS One. 2021; 16(2):e0247683.
    View in: PubMed
    Score: 0.007
  17. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet. 2000 May 01; 9(8):1145-59.
    View in: PubMed
    Score: 0.007
  18. Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome. Cereb Cortex. 2020 03 14; 30(3):969-988.
    View in: PubMed
    Score: 0.007
  19. Alternative splicing in the murine and human FXR1 genes. Genomics. 1999 Jul 15; 59(2):193-202.
    View in: PubMed
    Score: 0.006
  20. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol. 2018 Sep; 118(3):518-524.
    View in: PubMed
    Score: 0.006
  21. Multisite Investigation of Outcomes With?Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 01 22; 11(2):181-191.
    View in: PubMed
    Score: 0.006
  22. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
    View in: PubMed
    Score: 0.006
  23. Selection against mutant alleles in blood leukocytes is a consistent feature in Incontinentia Pigmenti type 2. Hum Mol Genet. 1996 Nov; 5(11):1777-83.
    View in: PubMed
    Score: 0.005
  24. Genetic variation and evolutionary stability of the FMR1 CGG repeat in six closed human populations. Am J Med Genet. 1996 Jul 12; 64(1):220-5.
    View in: PubMed
    Score: 0.005
  25. Haplotype and interspersion analysis of the FMR1 CGG repeat identifies two different mutational pathways for the origin of the fragile X syndrome. Hum Mol Genet. 1996 Mar; 5(3):319-30.
    View in: PubMed
    Score: 0.005
  26. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
    View in: PubMed
    Score: 0.005
  27. Population survey of the human FMR1 CGG repeat substructure suggests biased polarity for the loss of AGG interruptions. Hum Mol Genet. 1995 Dec; 4(12):2199-208.
    View in: PubMed
    Score: 0.005
  28. A muscle-specific DNase I-like gene in human Xq28. Hum Mol Genet. 1995 Sep; 4(9):1557-64.
    View in: PubMed
    Score: 0.005
  29. Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat Genet. 1995 Aug; 10(4):483-5.
    View in: PubMed
    Score: 0.005
  30. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle. 2015; 14(18):2985-95.
    View in: PubMed
    Score: 0.005
  31. De novo mutation in three families with multigenerational incontinentia pigmenti. Am J Hum Genet. 1994 Dec; 55(6):1279-81.
    View in: PubMed
    Score: 0.005
  32. Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. Nat Genet. 1994 Nov; 8(3):229-35.
    View in: PubMed
    Score: 0.005
  33. MBD5 haploinsufficiency is associated with sleep disturbance and disrupts circadian pathways common to Smith-Magenis and fragile X syndromes. Eur J Hum Genet. 2015 Jun; 23(6):781-9.
    View in: PubMed
    Score: 0.005
  34. A de novo deletion in FMR1 in a patient with developmental delay. Hum Mol Genet. 1994 Sep; 3(9):1705-6.
    View in: PubMed
    Score: 0.004
  35. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet. 1994 Sep; 8(1):88-94.
    View in: PubMed
    Score: 0.004
  36. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1594-603.
    View in: PubMed
    Score: 0.004
  37. Frequency and stability of the fragile X premutation. Hum Mol Genet. 1994 Mar; 3(3):393-8.
    View in: PubMed
    Score: 0.004
  38. Advances in molecular analysis of fragile X syndrome. JAMA. 1994 Feb 16; 271(7):536-42.
    View in: PubMed
    Score: 0.004
  39. Regional assignment of 19 X-linked ESTs. Hum Mol Genet. 1993 Nov; 2(11):1901-5.
    View in: PubMed
    Score: 0.004
  40. Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013 Jul 16; 13:74.
    View in: PubMed
    Score: 0.004
  41. Trinucleotide repeat instability: when and where? Nat Genet. 1993 Jun; 4(2):107-8.
    View in: PubMed
    Score: 0.004
  42. Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in fragile X syndrome. J Neurosci. 2013 Apr 24; 33(17):7548-58.
    View in: PubMed
    Score: 0.004
  43. Bmal1 and ?-cell clock are required for adaptation to circadian disruption, and their loss of function leads to oxidative stress-induced ?-cell failure in mice. Mol Cell Biol. 2013 Jun; 33(11):2327-38.
    View in: PubMed
    Score: 0.004
  44. Alternative splicing in the fragile X gene FMR1. Hum Mol Genet. 1993 Apr; 2(4):399-404.
    View in: PubMed
    Score: 0.004
  45. Triplet repeat mutations in human disease. Science. 1992 May 08; 256(5058):784-9.
    View in: PubMed
    Score: 0.004
  46. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med. 2012 Aug; 14(8):729-36.
    View in: PubMed
    Score: 0.004
  47. Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila. Hum Mol Genet. 2012 May 01; 21(9):2068-75.
    View in: PubMed
    Score: 0.004
  48. FXR1P but not FMRP regulates the levels of mammalian brain-specific microRNA-9 and microRNA-124. J Neurosci. 2011 Sep 28; 31(39):13705-9.
    View in: PubMed
    Score: 0.004
  49. Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. Hum Mol Genet. 2012 Jan 01; 21(1):57-65.
    View in: PubMed
    Score: 0.004
  50. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med. 2011 May; 17(5):559-65.
    View in: PubMed
    Score: 0.004
  51. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci. 2008 Jun; 122(3):710-5.
    View in: PubMed
    Score: 0.003
  52. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007 Jul; 47(1):51-9.
    View in: PubMed
    Score: 0.003
  53. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res. 2007 Jan 15; 313(2):244-53.
    View in: PubMed
    Score: 0.003
  54. Secretin receptor-deficient mice exhibit impaired synaptic plasticity and social behavior. Hum Mol Genet. 2006 Nov 01; 15(21):3241-50.
    View in: PubMed
    Score: 0.003
  55. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet. 2006 Jun 15; 15(12):1984-94.
    View in: PubMed
    Score: 0.003
  56. Benefits of telephone care over primary care for smoking cessation: a randomized trial. Arch Intern Med. 2006 Mar 13; 166(5):536-42.
    View in: PubMed
    Score: 0.002
  57. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron. 2005 Aug 04; 47(3):339-52.
    View in: PubMed
    Score: 0.002
  58. The DNA sequence of the human X chromosome. Nature. 2005 Mar 17; 434(7031):325-37.
    View in: PubMed
    Score: 0.002
  59. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet. 1994 Jul 15; 51(4):298-308.
    View in: PubMed
    Score: 0.002
  60. Somatic and germline instability of the ATTCT repeat in spinocerebellar ataxia type 10. Am J Hum Genet. 2004 Jun; 74(6):1216-24.
    View in: PubMed
    Score: 0.002
  61. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004 Feb; 7(2):113-7.
    View in: PubMed
    Score: 0.002
  62. Cytogenetic analysis of obsessive-compulsive disorder (OCD): identification of a FRAXE fragile site. Am J Med Genet A. 2003 Apr 01; 118A(1):25-8.
    View in: PubMed
    Score: 0.002
  63. Knockout mouse model for Fxr2: a model for mental retardation. Hum Mol Genet. 2002 Mar 01; 11(5):487-98.
    View in: PubMed
    Score: 0.002
  64. Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. Hum Mol Genet. 2001 Oct 15; 10(22):2557-67.
    View in: PubMed
    Score: 0.002
  65. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am J Hum Genet. 2001 Mar; 68(3):765-71.
    View in: PubMed
    Score: 0.002
  66. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet. 2000 Oct; 26(2):191-4.
    View in: PubMed
    Score: 0.002
  67. Filamin (FLN1), plexin (SEX), major palmitoylated protein p55 (MPP1), and von-Hippel Lindau binding protein (VBP1) are not involved in incontinentia pigmenti type 2. Am J Med Genet. 2000 Sep 04; 94(1):79-84.
    View in: PubMed
    Score: 0.002
  68. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000 May 25; 405(6785):466-72.
    View in: PubMed
    Score: 0.002
  69. Human homologue of the murine bare patches/striated gene is not mutated in incontinentia pigmenti type 2. Am J Med Genet. 2000 Mar 20; 91(3):241-4.
    View in: PubMed
    Score: 0.002
  70. Mutation analysis of the DKC1 gene in incontinentia pigmenti. J Med Genet. 1999 Nov; 36(11):860-2.
    View in: PubMed
    Score: 0.002
  71. Re-examination of factors associated with expansion of CGG repeats using a single nucleotide polymorphism in FMR1. Hum Mol Genet. 1998 Nov; 7(12):1935-46.
    View in: PubMed
    Score: 0.001
  72. X-linked situs abnormalities result from mutations in ZIC3. Nat Genet. 1997 Nov; 17(3):305-8.
    View in: PubMed
    Score: 0.001
  73. Interchromosomal duplications of the adrenoleukodystrophy locus: a phenomenon of pericentromeric plasticity. Hum Mol Genet. 1997 Jul; 6(7):991-1002.
    View in: PubMed
    Score: 0.001
  74. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum Mol Genet. 1997 Mar; 6(3):479-86.
    View in: PubMed
    Score: 0.001
  75. Predisposition to the fragile X syndrome in Jews of Tunisian descent is due to the absence of AGG interruptions on a rare Mediterranean haplotype. Am J Hum Genet. 1997 Jan; 60(1):103-12.
    View in: PubMed
    Score: 0.001
  76. Large domains of apparent delayed replication timing associated with triplet repeat expansion at FRAXA and FRAXE. Am J Hum Genet. 1996 Aug; 59(2):407-16.
    View in: PubMed
    Score: 0.001
  77. FMR1 in global populations. Am J Hum Genet. 1996 Mar; 58(3):513-22.
    View in: PubMed
    Score: 0.001
  78. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics. 1996 Jan; 97(1):122-6.
    View in: PubMed
    Score: 0.001
  79. Gonadal mosaicism for incontinentia pigmenti in a healthy male. J Med Genet. 1995 Nov; 32(11):887-90.
    View in: PubMed
    Score: 0.001
  80. 130 kb of DNA sequence reveals two new genes and a regional duplication distal to the human iduronate-2-sulfate sulfatase locus. Genome Res. 1995 Aug; 5(1):71-8.
    View in: PubMed
    Score: 0.001
  81. The fragile X premutation in carriers and its effect on mutation size in offspring. Am J Hum Genet. 1995 May; 56(5):1147-55.
    View in: PubMed
    Score: 0.001
  82. Fragile X syndrome in a normal IQ male with learning and emotional problems. J Am Acad Child Adolesc Psychiatry. 1994 Nov-Dec; 33(9):1316-21.
    View in: PubMed
    Score: 0.001
  83. Loss of mutation at the FMR1 locus through multiple exchanges between maternal X chromosomes. Hum Mol Genet. 1994 Oct; 3(10):1823-7.
    View in: PubMed
    Score: 0.001
  84. Reliability of diagnostic assessment of normal and premutation status in the fragile X syndrome using DNA testing. Am J Med Genet. 1994 Jul 15; 51(4):339-45.
    View in: PubMed
    Score: 0.001
  85. Robust amplification and ethidium-visible detection of the fragile X syndrome CGG repeat using Pfu polymerase. Am J Med Genet. 1994 Jul 15; 51(4):522-6.
    View in: PubMed
    Score: 0.001
  86. High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome. Hum Mol Genet. 1993 Oct; 2(10):1659-65.
    View in: PubMed
    Score: 0.001
  87. Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet. 1993 Jul; 4(3):244-51.
    View in: PubMed
    Score: 0.001
  88. High-resolution mapping of probes near the X-linked lymphoproliferative disease (XLP) locus. Genomics. 1993 Jul; 17(1):163-70.
    View in: PubMed
    Score: 0.001
  89. Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics. 1993 Apr; 16(1):254-5.
    View in: PubMed
    Score: 0.001
  90. Direct versus indirect molecular diagnosis of fragile X mental retardation in 40 German families at risk. J Med Genet. 1993 Mar; 30(3):193-7.
    View in: PubMed
    Score: 0.001
  91. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet. 1993 Jan; 3(1):36-43.
    View in: PubMed
    Score: 0.001
  92. Frequent small amplifications in the FMR-1 gene in fra(X) families: limits to the diagnosis of 'premutations'. J Med Genet. 1992 Nov; 29(11):802-6.
    View in: PubMed
    Score: 0.001
  93. Genome analysis and the human X chromosome. Science. 1992 Oct 02; 258(5079):103-9.
    View in: PubMed
    Score: 0.001
  94. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992 Sep; 1(6):397-400.
    View in: PubMed
    Score: 0.001
  95. PCR amplification and analysis of yeast artificial chromosomes. Genomics. 1992 Aug; 13(4):1303-6.
    View in: PubMed
    Score: 0.001
  96. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature. 1992 Jul 16; 358(6383):239-42.
    View in: PubMed
    Score: 0.001
  97. Intragenic probe used for diagnostics in fragile X families. Am J Med Genet. 1992 Apr 15-May 1; 43(1-2):192-6.
    View in: PubMed
    Score: 0.001
  98. Characterization of a highly polymorphic dinucleotide repeat 150 KB proximal to the fragile X site. Am J Med Genet. 1992 Apr 15-May 1; 43(1-2):237-43.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.